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PROTECTION AGAINST 
IN JURY DURING ISCHEMIA 
AND REPERFUSION BY 
ACADESINE DERIVATIVES 
GP-1-468 AND GP-1-668 
Studies in the transplanted 
rat heart 
Background. Acadesine (AICAr: 5-amino-4-imidazole carboxamide ribo- 
side) has been shown to atford sustained protection against injury during 
ischemia and reperfusion. The present studies used the heterotopically 
transplanted rat heart to assess the protective properties of two new 
acadesine analogs: GP-1-468 and GPll-668. Methods and results. Hearts 
were excised, arrested with a 2-minute infusion of cardioplegic solntion, 
and subjected to 4 hours of global ischemia (20 ° C) with cardioplegic 
reinfusion for 2 minutes every 30 minutes. The hearts were then trans- 
planted (1 hour of additional ischemia) into the abdomens of recipient rats 
and reperfused in situ for 30 minutes or 24 hours. The hearts were then 
excised, perfused aerobically for 20 minutes, and contractile function was 
assessed. GP-1-468 or GP-1-668 was administered to donor rats (20 mg/kg 
intravenously, 30 minutes before excision). They were also added to the 
cardioplegic solution (10 gmol/L for GP-1-468, 5 gmol/L for GP-1-343, the 
active metabolite of GP-1-668) and were also given to recipient rats (20 
mg/kg intravenously, 30 minutes before transplantation, so that the drugs 
were present during reperfusion). Nine groups of hearts were studied. 
Three groups of studies were carried out (n = 24 transplants for each 
group). The first group of hearts was reperfused for 30 minutes, the second 
group was reperfused for 24 hours, and the third group was transplanted 
but not reperfused; instead, they were frozen at the end of 5 hours of 
ischemia and taken for metabolite analysis. Within each group were three 
subgroups (n = 8 per group) receiving GP-1-468, GP-1-668, or saline 
solution. In the 30-minute reperfusion group the recoveries of left ventric- 
ular developed pressure were 88 - 4, 87 ± 7, and 50 ± 9 mm Hg, 
respectively (p < 0.05 versus saline-treated controls); left ventricular 
volumes (recorded at 12 mm Hg) were 112 _ 20, 132 -+ 28, and 41 + 9 pl, 
respectively (p < 0.05 versus saline-treated controls), and coronary flows were 
13.1 _ 0.7, 13.4 __. 1.0, and 9.9 ± 0.5 ml/min, respectively (p < 0.05 versus 
saline-treated controls). In addition to improving functional recovery, the two 
analogs increased the tissue content of adenosine at the end of the ischemic 
period (5.4 - 0.6 and 7.3 ± 0.5/.tmol/gm dry weight, respectively, versus 2.7 ± 
0.4/.tmol/gm dry weight in the saline-treated controls;p < 0.05); however, they 
did not influence adenosine triphosphate or its catabolites. In the 24-hour 
reperfusion group the corresponding values were 77 - 6 and 88 - 6 versus 
35 ± 4 mm Hg for left ventricular developed pressure (p < 0.05), 111 ± 9 and 
121 ± 11 versus 41 ± 8/.d for left ventricular volume (p < 0.05), and 13.7 ± 
0.7 and 13.0 ± 0.6 versus 11.7 ± 0.7 ml/min for coronary flow (no significant 
difference). Thus both analogs aforded an early and comparable degree of 
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protection of contractile function that was sustained even after 24 hours of 
reperfusion. Conclusions. Both GP-1-468 and GP-1-668 increase the rate and extent 
of early postischemic recovery, and this protection is sustained for at least 24 hours. 
These beneficial actions were associated with an increase of the tissue content of 
adenosine during ischemia, but they appeared to be independent of the status of the 
high-energy metabolism. (J THORAC CARDIOVASC SURG 1995;110:752-61) 
A growing body of evidence indicates that acadesine (AICAr: 5-amino-4-imidazole carbox- 
amide riboside) can exert a variety of beneficial 
effects on the cardiovascular system. It is thought o 
increase regional blood flow by increasing local 
adenosine concentration.l' 2 It can inhibit neutrophil 
activation, 3 suppress platelet activation and intra- 
coronary thrombosis, 4'5 prevent oxidant-induced 
injury, 6 inhibit glycolysis, 7 and potentiate the pro- 
tective mechanisms induced by myocardial precon- 
ditioning. 8 Using the isolated crystalloid-perfused 
rat heart 9 and the blood-perfused transplanted rat 
heart, 1° we have reported previously that acadesine 
increases the myocardial adenine nucleotide and 
adenosine contents at the end of ischemia and 
improves the postischemic recovery of contractile 
function. Furthermore, we were able to demonstrate 
that acadesine could afford a sustained protection of 
cardiac contractile function for at least the first 24 
hours of reperfusion, which suggests that it may act 
by reducing necrosis rather than simply accelerating 
recovery from stunning. In other models of myocar- 
dial ischemia-reperfusion injury, the benefits of 
acadesine are accompanied by elevated adenosine 
levels.1, 2 However, the benefit can be attenuated if 
adenosine formation is suppressed or adenosine 
receptor blocked. 11' 12 
Recently, two acadesine analogs, GP-1-468 (5- 
amino-5-deoxy-/3-D-ribofuranosylimidazole 4N-[(4- 
chlorophenyl)methyl]carboxamide) and GP-1-668 
(the soluble monophosphate of the active species 
GP-1-343; 5-amino-1-/3-D-ribofuranosylimidazole 4N- 
[(4-nitrophenyl)methyl]carboxamide), hav  been syn- 
thesized (Fig. 1). These analogs have a greater 
potency than acadesine in terms of their ability to 
augment extracellular adenosine levels during 
adenosine triphosphate breakdown (such as oc- 
curs in ischemia), and these agents have been 
suggested to possess antiischemic properties that 
are mediated by adenosine. 13' 14 However, these 
two comp0unds differ with respect o other phar- 
macologic properties. Only GP-1-468 is a potent 
inhibitor o f  lipid peroxidation by virtue of its 
chemical structure, 14 whereas GP-1-668 inhibits 
intravascular thrombosis in vivo, 15' 16 an effect not 
shared by GP-1-468. 
With these different pharmacologic profiles in 
mind, we designed the present study with two aims. 
First, we sought to compare the protective proper- 
ties of the two acadesine analogs in relation to their 
ability to reduce injury occurring during global 
ischemia and reperfusion using the same model in 
which acadesine was previously shown to be effec- 
tive, even after 24 hours of reperfusion. Second, we 
investigated whether these analogs exert any effect 
on the tissue content of adenosine and high-energy 
phosphates at the end of the ischemic period. 
Materials and methods 
Animals. Male homozygous Lewis rats, weighing 200 to 
250 gm, were used. All animals received humane care in 
compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the National Academy 
of Sciences and published by the National Institutes of 
Health (NIH No. 86-23, revised 1985). 
Surgical procedures 
Excision and storage of hearts. Each rat was anesthe- 
tized with pentobarbital (60 mg/kg intraperitoneally) and 
the lungs were mechanically ventilated through a trache- 
ostomy at a rate of 55 strokes/min with a ventilation 
pressure of 12 to 14 mm Hg. The chest was opened and 
the venae cavae and pulmonary veins were isolated; 
heparin was administered (1000 IU/kg intravenously). The 
venae cavae and pulmonary veins were then ligated and 
the heart was excised and placed in cold (4 ° C) saline 
solution. The aorta was rapidly cannulated and St. Tho- 
mas' Hospital cardioplegic solution (containing, in milli- 
moles per liter: NaC1 110.0 KC1 16.0, MgC12 16.0, CaC12 
1.2, and NaHCO3 10.0 at pH 7.8) at 20 ° C was infused for 
2 minutes at a constant pressure of 45 mm Hg. Each heart 
was then stored for 4 hours at 20 ° C; during this time it 
was immersed in the same cardioplegic solution and 
reinfused with the solution for 2 minutes every 30 minutes. 
This protocol, which was identical to the one used in our 
previous tudy with acadesine, a° was chosen to investigate 
and to compare the potential benefit of the acadesine 
analogs GP-1-468 and GP-1-668 in the presenee of severe 
functional impairment. 
Transplantationprocedure. Th  abdomen of an anesthe- 
tized recipient rat was opened through amidline incision 
and the abdominal aorta and inferior vena cava were 
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Fig. 1. Chemical structure of acadesine and its analogs GP-1-468 and GP-1-668. 
exposed. The donor heart (which had been stored for 4 
hours) was removed from the hypothermic chamber and, 
the aorta and pulmonary artery were anastomosed (end to 
side) to the abdominal aorta and inferior vena cava of the 
recipient rat with 10-0 Ethicon sutures (Ethicon, Inc., 
Somerville, N.J.). The heart was maintained at 18 ° to 
22 ° C during the implantation period; this was achieved by 
wrapping it in a swab that was regularly irrigated with cold 
(60 to 10 ° C) saline solution. The duration of the implan- 
tation period was standardized at 60 minutes for all 
studies to minimize variability between experiments. 
Hearts were then repeffused with blood, in situ, for 30 
minutes or 24 hours. When the hearts were reperfused for 
24 hours, the abdominal wall of the recipient rats was 
closed in two layers and the animals were allowed to 
recover in an unrestrained state with free access to food 
and water. 
Assessment of eardiac funetion after transplantation 
and reperfusion. Thirty minutes or 24 hours after implan- 
tation and reperfusion of the transplanted hearts, each 
recipient rat was again anesthetized, the right femoral 
vein was exposed, and heparin was administered (1000 
IU/kg intravenously). The abdomen was reopened and the 
transplanted heart was excised and placed in cold (4 ° C) 
saline solution. The aorta was rapidly cannulated and each 
heart perfused aerobically with crystalloid perfusion 
fluid 17 (containing, in millimoles per liter: glucose 11.1, 
NaC1 118.5, KC1 4.8, MgSO4 1.2, KH2PO 4 1.2, NaHCO 3 
25.0, CaC12 1.4 at pH 7.4 when gassed with 95% 02 plus 
5% CO2) at a constant pressure (75 mm Hg) in the 
Langendorff mode TM at 37 ° C for 20 minutes. Before use, 
perfusion and cardioplegic solutions were filtered through 
a 5/xm pore filter. A silver pacing wire was connected to 
the right atrium, a second pacing wire was attached to the 
aortic cannula, and hearts were paced at a fixed rate of 320 
beats/min. After 20 minutes of reperfusion, coronary flow 
was measured and function curves for left ventricular 
developed pressure (LVDP) were constructed with an 
intraventricular balloon by progressively increasing its 
volume to achieve nd-diastolic pressures (LVEDP) of 0, 
4, 8, 12, 16, and 20 mm Hg. In this manner, contractile 
function was assessed by subjecting hearts to an identieal 
ventricular load and avoiding overdistention of the left 
ventricle (LV) that may have arised from fixed increments 
of predetermined balloon volumes. 
Study groups. In all, nine groups of hearts (n = 8 per 
group) were studie& These were divided into three 
groups, each with three subgroups. In one group, the 
hearts were transplanted but were not reperfused; instead, 
they were freeze clamped at the end of 5 hours of ischemia 
(4 hours of storage plus 1 hour of transplantation) and 
were then taken for metabolite analysis. In the second 
group, hearts were transplanted and then reperfused for 
30 minutes. In the third group, hearts were reperfused for 
24 hours. Within each group there were three subgroups. 
One subgroup (controls) received saline solution. One 
subgroup received GP-1-468 that was given (20 mg/kg, 
intravenously) to the donor rat 30 minutes before the 
excision of the heart. The drug was also included as an 
additive (10/xmol/1) in the cardioplegic solution that was 
infused before and during ischemia, and it was also given 
(20 mg/kg, intravenously) to the recipient rat 30 minutes 
before implantation in order that it be present during 
reperfusion. The third subgroup received GP-1-668. 
Again, it was given (20 mg/kg, intravenously) 30 minutes 
before the excision of the heart, it was included as an 
additive to the cardioplegic solution (however, GP-1-343, 
5/xmol/1, the active metabolite of GP-1-668, was used in 
place of GP-1-668), and the drug was given (20 mg/kg, 
intravenously) to the recipient rat 30 minutes before 
implantation, so as to be present during reperfusion of the 
transplanted heart. 
For comparative purposes, eight hearts were not sub- 
jected to ischemia but were perfused aerobically with 
crystalloid solution for 20 minutes and then used for the 
measurement of control aerobic cardiac function and 
metabolism. 
Analysis of high-energy phosphates and their catabo- 
lites. Frozen hearts were lyophilized and homogenized in 
3 ml of perchloric acid (0.6 mol/L) at 4 ° C. Ea¢h homo- 
genate was then centrifuged at 2000 g for 10 minutes at 
4 ° C. A portion (0.6 tal) of the supernatant was then 
neutralized by the addition of 0.045 ml potassium carbon- 
ate (5 mol/L); the mixture was left on ice for 5 minutes 
and then centrifuged as previously. The supernatant was 
passed through a 0.45/xm mesh nylon filter and stored at 
-20°C before high-performance liquid chromatography 
analysis. I9 Nucleotides and their metabolites were ana- 
lyzed with a Waters high-performance liquid chromatog- 
raphy system (Waters Corp., Rochester, Minn.) compris- 
ing two 510 pumps, a 1 ml static mixing chamber, aWISP 
712 automated sample injector with refrigeration unit 
(Waters HPLC System, Waters Corp., S. San Francisco, 
Calif.), and a 441 detector set at 254 nm. The following 
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intermediates were measured: adenosine triphosphate 
(ATP), adenosine diphosphate (ADP), adenosine mono- 
phosphate (AMP), inosine monophosphate (IMP), aden- 
osine, inosine, and hypoxanthine. The values obtained 
were used to calculate the following indexes of myocardial 
energy status:: 
Adenylate pool = [ATP + ADP + AMP] 
Energy charge potential = 
[0.5 ADP + ATP]/[ATP + ADP + AMP] 
The limits of detection for quantification of spectrally 
matched metabolites in 50/xl aliquots taken from the 3 ml 
samples were 5 nmol/gm tissue for the nucleotides and 10 
nmol/gm for the nucleosides. 
Exclusion criteria. Experiments in which the support 
animal died as a consequence of bleeding and hearts in 
which intraventricular thrombosis developed were ex- 
cluded. 
Expression of results and statistical analyses. LVDP 
was calculated as the difference between peak systolic 
pressure and LVEDP. Coronary flow (milliliters per 
minute) was measured by timed collection of coronary 
elttuent. Tissue metabolite contents were expressed as 
micromoles per gram dry weight. All results were ex- 
pressed as means -+ standard error of the means. Analysis 
of variance was used for comparison of  more than two 
means; when a significant F value was obtained, compar- 
isons between the different groups were carried out by 
means of Tukey's test. A difference was considered statis- 
tically significant when p < 0.05. 
Results 
From the 80 hearts initially entered into the study, 
only five hearts were excluded: two because of 
arterial bleeding after transplantation (in the saline 
solution and GP-1-668 groups) and three because of 
formation of intraventricular thromboses after 24 
hours of reperfusion (two in the GP-1-468 group 
and one in the saline solution group). The excluded 
hearts were replaced according to the randomiza- 
tion protocol. 
Metab01ic studies after 5 hours of hypothermic 
ischemia. The results in Fig. 2 show that in the 
saline-treated controls, the tissue content of adeno- 
sine at the end of 5 hours of hypothermic schemia 
increased from 0.1 _+ 0.01 p~mol/gm dry weight (the 
value in aerobically perfused hearts) to 2.8 _+ 0.4 
/xmol/gm d13r weight (p < 0.05). By contrast, hearts 
treated with GP-1-468 had an adenosine content 
that was fwice that observed in saline-treated con- 
trols. Hearts treated with GP-1-668 had an even 
higher vaiue (7.3 -+ 0.5 /zmol/gm dry weight; p < 
0.05 versus saline-treated controls and the GP-1- 
468-treated group). The greater adenosine content 
in the GP-1-468- and GP-1-668-treated hearts was 
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Fig. 2. Tissue adenosine content at the end of 5 hours of 
ischemia in saline-treated hearts and hearts receiving 
GP-1-468 or GP-1-668 (n = 8 per group). The bars 
indicate the standard error of the mean. *p < 0.05 when 
compared with saline-treated controls; ?p < 0.05 when 
compared with the GP-1-468-treated group. 
reflected by a decreased hypoxanthine content (Ta- 
ble I). The content of adenosine triphosphate and its 
catabolites, together with the adenylate charge po- 
tential, were substantially reduced by ischemia in 
the saline-treated controls. This decrease was not 
significantly affected by the treatment with either of 
the two acadesine analogs (Table I). 
Functional studies after 30 minutes of reperfu- 
sion 
Contractile function. The results in Fig. 3 show 
that, in comparison with nonischemic aerobic con- 
trols, saline-treated hearts subjected to 5 hours of 
hypothermic ischemia had substantial injury and a 
deterioration of systolic (Fig. 3, A) and diastolic 
(Fig. 3, B) function. In contrast, the administration 
of either GP-1-468 or GP-1-668 afforded compara- 
ble, substantial, and significant improvements in 
postischemic cardiac function over the entire range 
of LVEDP and LV volumes. Taking an LVEDP of 
12 mm Hg as an example, the recovery of both 
LVDP and the LV volume increased from 50 + 9 
mm Hg and 41 + 9/xl in the saline-treated controls 
to 88 + 4 mm Hg and 112 + 20/xl in the GP-1-468- 
treated hearts and to 87 + 7 mm Hg and 132 _+ 28 
/xl in the GP-1-668-treated hearts (p < 0.05 in all 
instances). 
Coronary flow. The postischemic recovery of cor- 
onary flow (Fig. 4, A) in saline-treated controls was 
significantly decreased to 78% of the aerobic ontrol 
value (9.9 + 0.5 versus 12.6 _+ 0.4 ml/min;p < 0.05). 
However, coronary fiow completely recovered in 
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Table I. Tissue metabolite content in aerobic control hearts and hearts at the end of 5 hours of ischemia 
(4 hours of hypothermic storage plus 1 hour of transplantation) that were treated with saline solution or the 
acadesine analogs GP-1-468 and GP-1-668 (see text for details) 
Tissue content (txmol/gm dry w o 
Group n ATP ADP AMP IMP INO HYP AP ACP 
Aerobic controls 8 23.3 -+ 0.2 3.6 + 0.1 4.3 _+ 0.2 ND 0.05 ± 0.01 ND 31.2 _+ 0.5 0.81 _+ 0.01 
Saline solution 8 1.0 -+ 0.2 1.6 ,+ 0.2 9.7 .+ 0.6 4.4 ± 0.4 7.73 _+ 1.11 2.81 _+ 0.33 12.3 ± 0.9 0.14 ,+ 0.02 
GP-1-468 8 1.4 .+ 0.2 2.2 ± 0.1 10.7 ± 0.5 4.3 ± 4.4 7.78 -+ 0.58 1.89 _+ 0.21" 14.3 -4- 0.7 0.17 ± 0.01 
GP-1-668 8 1.4 ± 0.2 1.9 + 0.1 10.9 _+ 0.6 4.5 -+ 0.3 6.80 .+ 0.45 1.38 ± 0.17" 14.2 ± 0.6 0.17 ± 0.02 
ATP, Adenosine triphosphate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; IMP, inosine monophosphate; INO, inosine; HYP, 
hypoxanthine; AP, adenylate pool; ACP, adenylate charge potential; ND, not detected. 
*p < 0.05 versus aline-treated groups. 
hearts treated with either GP-1-468 or GP-1-668 
(13.1 _+ 0.7 and 13.4 _+ 1.0 tal/min, respectively;p -- 
no significant difference versus aerobic controls). 
Metabolic and functional studies after 24 hours 
of reperfusion 
Contractile function. The results in Fig. 5 show 
that, after 24 hours of reperfusion, hearts in the 
saline-treated group had a sustained eterioration 
of contractile function that was even more severe 
than that observed after 30 minutes of reperfusion. 
Thus, at an LVEDP of 12 mm Hg, LVDP was 35 _+ 
4 mm Hg compared with 50 _+ 9 mm Hg after 30 
minutes of reperfusion and 138 _+ 8 mm Hg in the 
aerobic controls. Again, however, the administra- 
tion of either GP-1-468 or GP-1-668 resulted in a 
sustained and significant improvement in the recov- 
ery of systolic and diastolic function at all LVEDPs. 
Taking an LVEDP of 12 mm Hg as an example, the 
recoveries of LVDP and LV volume were increased 
from 35 + 4 mm Hg and 41 _+ 8 /xl in the 
saline-treated group to 77 + 6 mm Hg and 111 + 9 
B1 in the GP-1-468-treated group and to 84 _+ 6 mm 
Hg and 121 _+ 11/xl in the GP-1-668-treated group 
(p < 0.05 in all instances). In contrast with the 
saline-treated group, there was no significant de- 
terioration in function between 30 minutes and 24 
hours of reperfusion i  hearts treated with GP-1-468 
or GP-1-668. 
Coronmy flow. After 24 hours of reperfusion, the 
mean coronary flow (Fig. 4, B) in the saline-treated 
group recovered to a level similar to that observed in 
aerobically perfused hearts (11.7 _+ 0.7 versus 12.6 + 
0.4 ml/rnin, respectively). The values for coronary 
flow in the hearts treated with GP-1-468 (13.7 _ 0.7 
tal/min) and those treated with GP-1-668 (13.0 --- 
0.6 tal/min) were also similar to the values in the 
saline-treated hearts and in the nonischemic on- 
trols. 
Discussion 
The present studies with the heterotopically 
transplanted rat heart have shown that two analogs 
of acadesine can confer considerable protection 
against injury during ischemia nd reperfusion. This 
protection (measured on the basis of an ex vivo 
assessment of cardiac function) is apparent as soon 
as 30 minutes after the onset of reperfusion. How- 
ever, this protection is sustained, and indeed en- 
hanced, after 24 hours of in vivo reperfusion, which 
suggests that the protective ffect of the drugs is 
more likely to involve a redu¢tion in the extent of 
necrosis rather than an acceleration of the recovery 
from stunning. 
A number of additional observations can be made 
that may shed some light on the mechanism by 
which protection is a¢hieved. First, the protection 
afforded by GP-1-468 is almost identical to that 
provided by GP-1-668. This similarity would suggest 
that any differences in secondary pharma¢ologic 
properties between these compounds are unlikely to 
be important determinants of protection. Second, 
comparison of the results of the present study with 
those of our previous tudy 1° (which used an iden- 
tical model and protocol) revcals that the quantita- 
tive and qualitative characteristics of the protection 
of contractile function are virtually identical to those 
observed with the parent compound, a¢adesine. 
Again, this would suggest hat the secondary phar- 
macologic properties of these molecules may be 
relatively unimportant in influencing functional end 
points of injury. 
Although GP-1-468, GP-1-668, and acadesine 
may act in a similar manner in terms of influencing 
postischemic recoveries of LVDP, LV volume, and 
coronary flow, we cannot rule out the possibility that 
differences in thcir secondary pharmacologic prop- 
ertics (e.g, in relation to antithrombotic and anti- 
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lipid peroxidative properties) may beneficially af- 
fect end points not measured in the present 
studies. 
Chemical structure and adenosine-regulating ac- 
tivity of GP-.1-468 and GP-1-668. Acadesine, the 
patent molecule, is effective in reducing myocardial 
injury induced by ischemia and reperfusion in a 
variety of settings in different species} '9-11 This 
activity is prevented if endogenous adenosine is 
suppressed or adenosine receptors are blocked, 
which indicates mediation by local adenosine. 11' 12 
Moreover, recent studies indicate that acadesine 
attenuates myocardial injury in patients undergoing 
coronary artery bypass graft operations. 2°GP-1-468 
and GP-1-668 are two of a series of structural 
analogs of acadesine (see Fig. 1), synthesized to 
improve on the ability of acadesine to augment 
extracellular adenosine during periods of stress 
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when adenosine triphosphate is catabolized (as dur- 
ing myocardial ischemia). GP-1-668 is a soluble 
5'-monophosphate prodrug, which is metabolized 
rapidly in vivo (half-life < 1 minute) to GP-1-343, 
the active dephosphorylated cornpound. In vitro 
studies use GP-1-343, whereas GP-1-668 is admin- 
istered for in vivo studies. However, in both cases 
the activity resides with GP-1-343 and thus the two 
compounds are virtually interchangeable. GP-1-468 
and GP-1-343 are sevenfold to tenfold more effec- 
tive than acadesine at inhibiting the use of radiola- 
belled extracellular adenosine by cultured endothe- 
lial cells (J. Barankiewicz, unpublished observation, 
1992). The mechanism by which acadesine, GP-1- 
468, and GP-1-343 regulate adenosine levels is 
currently the subject of intense investigation. Like 
the parent molecule, GP-1-468 and GP-1-343 im- 
prove postischemic contractile function in the iso- 
lated buffer-perfused rat heart. This effect can be 
prevented by the coadministration f the adenosine 
receptor antagonist 8-SPT. Receptor binding studies 
indicate that these compounds have extremely low 
affinity for adenosine A 1 and A 2 receptors with less 
than 20% binding at 10 -3 mol/L (A. Foster, unpub- 
lished observation, 1992), thereby supporting the 
notion that their adenosinergic activity is mediated 
by endogenous adenosine rather than a direct effect 
on adenosine receptors. 
Potential advantages of GP-1-468 and GP-1-668 
over acadesine and the reason for the search for 
new acadesine analogs. The ¢linical e~¢acy of 
a¢adesinc in redu¢ing perioperative myocardial in- 
jury and other adverse cardiovascular outcomes in 
patients undergoing coronary artery bypass grafting 
indicates that adenosine-regulating agents represent 
a new class of therapeutic agent for the treatment of 
ischemic heart disease. Consequently, it is appropri- 
ate to develop a series of agents with differing 
profiles and, consequently, differing applications for 
the treatment of stable angina, unstable angina, 
acute myo¢ardial infarction, and other ischemic 
syndromes. For example, a¢adesine has limited oral 
bioavailability (<10%) and a short half-life; hence 
its use to treat chronic ischemic conditions in this 
delivery form might be limited. GP-1-468 was devel- 
oped as an orally active adenosine-regulating agent. 
It has an oral bioavailability in dogs of about 30% 
and an extended half-life (from 30 minutes to ap- 
proximately 8 hours). Furthermore, GP-1-468 and 
GP-1-668 are more potent and more eEicacious than 
acadesine. For example, in the isolated heart sub- 
je¢ted to is¢hemia and reperfusion, acadesine is 
optimal at a concentration of 20 /,Lmol/L, which 
results in an improved functional recovery. 9' 11 In 
the same preparation both GP-1-468 and GP-1-343 
are optimal at 5/~mol/LJ 2' 14 This enhanced benefit 
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is consistent with their augmented adenosine-regu- 
lating activity. Likewise, in the current experiments, 
doses of the analogs that were lower than acadesine 
doses were required to elicit protection. 
Possible mechanisms of cardioprotection by 
GP-1-468 and GP-1-668. In the present study the 
protective i effects of both analogs on contractility 
and vascular function were unrelated to the conser- 
vation of high-energy phosphate metabolites at the 
end of ischemia; however, they were ass0ciated with 
a greater accumulation of tissue adenosine. Cer- 
tainly, this finding is consistent with adenosine being 
the mediator of the protection, a conclusion sup- 
ported by studies in which 8-SPT blocked the im- 
provement in functional recovery that was elicited 
by the two analogs in an isolated heart preparation. 
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Moreover, adenosine xerts a variety of beneficial 
effects on the myocyte and endothelial cells 21 and 
also on leukocytes 21-23 and platelets. 24 Indeed, the 
mechanisms by which adenosine alleviates i chemia- 
reperfusion injury have not been defined but are 
suggested to include the following: (1) stimulation 
of glycolytic flUX; 25 (2) inhibition of lipolysis, which 
thereby stabilizes cellular membranes and decreases 
intracellular lactate and subsequent acidosis; 26 (3) 
an antiadrenergic effect that reduces the release of 
norepinephrine from sympathetic nerve endings; 27 
and (4) an ability to inhibit superoxide generation by 
neutrophils,2a, 22 neutrophil plugging, 23 and platelet 
aggregation. 24 The similarity of protection afforded 
by both GP-1-468 and GP-1-668 suggests that their 
adenosine-regulating activity is primarily responsi- 
bie for the benefits observed, and their secondary 
pharmacologic characteristics, such as inhibition of 
lipid peroxidation by GP-1-468, do not contribute 
substantially in this model. These results also imply 
that the inhibition of platelet activation by GP-1-668 
but not by GP-1-468 is not a contributory factor to 
the protection of the transplanted heart. 
In contrast o the forgoing, it should be noted 
that, using an identical experimental preparation, 
we 2s have shown that the administration of adeno- 
sine itself at the end of an ischemic period results in 
only a short-term benefit hat is lost by 24 hours of 
reperfusion. Because the two analogs induced a 
sustained protective ffect, a factor or factors other 
than adenosine could also contribute. Alternatively, 
the timing of drug administration may also be 
important, and a protocol that involves a pretreat- 
ment period could help to precondition the heart 
from any subsequent injury. We have not fully 
explored the issues related to the timing of drug 
administration, but the protocol of the present study 
matched that of our earlier study a° to permit com- 
parison of the analogs to the parent acadesine. 
Clinical relevance and applieability. The ability 
of the two acadesine analogs to improve the func- 
tional recovery after a period of ischemia might find 
important clinical applications in cases in which the 
onset and duration of ischemia are known. In this 
connection, routine cardiac surgery and cardiac 
transplantation are areas in which these drugs may 
be used to reduce the morbidity and mortality 
associated with impaired cardiac function. 
The potential clinical application of acadesine 
has been investigated in three placebo-controlled, 
double-blind, multicenter studies that have evalu- 
ated the efficacy of acadesine in reducing cardiovas- 
cular complications in patients undergoing coronary 
bypass grafting. 2°' 29-31 In all the studies, the admin- 
istration of acadesine tended to decrease, and in 
some instances, such as the incidence of periopera- 
tive myocardial infarction and stroke, it achieved a
level of statistical significance. A fourth multicenter 
study investigating the efficacy of acadesine against 
ischemic events in patients undergoing coronary 
bypass grafting was recently completed in the 
United States during 1994. This study involved more 
than 2500 patients, and it showed that although 
acadesine tended to reduce the incidence of perio- 
perative cardiovascular events, this difference did 
not achieve statistical significance. The complete 
results have yet to be presented or published. It 
might be argued that in these studies end points 
such as myocardial infarction, cardiac death, and 
stroke were used rather than other functional and/or 
structural indexes as in this current study. Indepen- 
dently of the controversy on appropriate indexes 
used for the assessment of efficacy of the drug, it 
should be emphasized that substantial experimental 
and clinical data support a beneficial effect of ade- 
nosine-regulating agents against injury sustained 
during ischemia and reperfusion 31 and that the 
search for agents with pharmacodynamic properties 
and efficacy greater than those of acadesine should 
be continued. 
Conclusions 
The two acadesine analogs, GP-1-468 and GP-1- 
668, accelerate the rate and extent of postischemic 
recovery and afford sustained prote¢tion of ¢ardiac 
function against injury during ischemia nd reperfu- 
sion. These effects were associated with an increase 
of tissue content of adenosine during ischemia but 
they appeared to be independent of the status of the 
high-energy metabolism. 
The statistical advice of Mr. N. Taub is gratefully 
acknowledged. 
REFERENCES 
1. Gruber HE, Hoffer ME, McAllester DR, et al. In- 
creased adenosine concentration i btood from isch- 
emic myocardium by AICA riboside. Circulation 
1989;80:1400-11. 
2. Young MA, Mullane KM. Progressive cardiac dys- 
function with repeated pacing-induced ischemia: pro- 
tection by AICA-riboside. Am J Physiol 1991;261: 
H1570-7. 
3. Cronstein BN, Eberle MA, Gruber HE, Levin RI. 
Methotrexate inhibits neutrophil function by stimulat- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 3 
Galihanes et aL 7 6 1 
ing adenosine release from connective tissue cells. 
Proc Natl Acad Sci U S A 1991;88:2441-5. 
4. Bullough DA, Zhang C, Mullane KM. Acadesine 
(AICA riboside) inhibits platelet aggregation i hu- 
man whole blood [Abstract]. Int J Purine Pyrimidine 
Res 1991;2(Suppl 1):66. 
5. Henry CA, Young M, Zhang C, et al. Adenosine 
release from red cells mediates inhibition of platelet 
aggregation by acadesine and delays post-thrombo- 
lytic reocclusion in dogs. Circulation 1991;84(Suppl): 
II246. 
6. Bullough DA, Fox M, Potter S, et al. AICA riboside 
protects myocardial tissue from repeffusion injury 
and oxidant induced amage. FASEB J 1991;5:A1436. 
7. Vincent MF, Bontemps F, Van Den Berghe G. Inhi- 
bition of glycolysis by 5-amino-24-imidazolecarbox- 
amide riboside in isolated rat hepatocytes. Biochem J 
1992;281:267-72. 
8. Tsuchida A, Liu GS, Mullane K, Downey JM. 
Acadesine lowers temporal threshold for the myocar- 
dial infarct size limiting effect of preconditioning. 
Cardiovasc Res 1993;27:116-20. 
9. Galifianes M, Mullane KM, Bullough D, Hearse DJ. 
Acadesine and myocardial protection: studies of time 
of administration and dose-response r lations in the 
rat. Circulation 1992;86:598-608. 
10. Galifianes M, Bullough D, Mullane KM, Hearse DJ. 
Sustained protection by acadesine against ischemia- 
and reperfusion-induced injury: studies in the trans- 
planted rat heart. Circulation 1992;86:589-97. 
11. Bullough DA, Fox MH, Mullane KM. Acadesine 
regulates adenosine to improve post-ischemic func- 
tion in the isolated heart. J Mol Cell Cardiol 1992; 
24(Suppl III):S6. 
12. Magill MJ, Fox MH, Young MA, Mullane KM, 
Bullough DA. Adenosine mediates the cardioprotec- 
tive actions of GP-1-468 in the isolated heart. FASEB 
J 1993;7:Al19. 
13. Pan W, Mullane KM, Young MA. Anti-ischemic 
actMty of the novel adenosine-regulating a ent, 
GP-1-468, in a canine model of stable angina. FASEB 
J 1993;7:Al19. 
14. Bullough D, Drake L, Zhang C, Magill M, Mullane K. 
Dual antMschemic activity and inhibition of LDL 
oxidation represents wo independent mechanisms of
protection with GP-1-468. FASEB J 1994;8:A635. 
15. Montag A, Metzner K, Kopcho J, Mullane K, Young M. 
Adenosine-mediated antithrombotic effects of the 
novel adenosine-regulating agent GP-1-668. Pharma- 
cologist 1993;35:180. 
16. Montag A, Pan W, Mullane KM, Young MA. GP-1- 
668 enhances thrombolysis n combination with aspi- 
rin in the rabbit carotid artery. FASEB J 1994;8:A268. 
17. Krebs HA,'Henseleit K. Untersuchungen über die 
Harnstoffbitdung im Tierkörper. Hoppe Seylers Z 
Physiol Chem 1932;210:33-66. 
18. Langendorff O. Untersuchungen am uberlebenden 
Saugethierherzen. Pflugers Arch 1895;61:291-332. 
19. Holliss DG, Humphrey SM, Morrison MA, Seelye 
RN. Reverse phase HPLC for rapid, comprehensive 
measurements of nucleotides, nucleosides and bases 
of the myocardial adenine pool. Anal Letters 1984; 
17(B18):2047-65. 
20. Leung J, Stanley T, Mathew J, et al. An initial 
multicenter, randomized controlled trial on the safety 
and efficacy of acadesine in patients undergoing cor- 
onary artery bypass graft surgery. Anesth Analg 1994; 
778:420-34. 
21. Cronstein BN, Levin RI, Belanoff J, Weissman G, 
Hirschhorn R. Adenosine: an endogenous inhibitor of 
neutrophil-mediated injury to endothelial cells. J Clin 
Invest 1986;78:760-70. 
22. Engler R. Consequences of activation and adenosine- 
mediated inhibition of granulocytes during myocar- 
dial ischemia. Fed Proc 1987;46:2407-12. 
23. Grisham MB, Hernandez LA, Granger DN. Adeno- 
sine inhibits ischemia-reperfusion-induced leukocyte 
adherence and extravasation. Am J Physiol 1989;257: 
H1334-9. 
24. Gerlach E, Becker BF, Nees S. Formation of adeno- 
sine by vascular endothelium: a homeostatic and 
antithrombogenic mechanism? In: Grelach E, Becker 
BF, eds. Topics and perspectives in adenosine re- 
search. Berlin: Springer, 1987:309-20. 
25. Wyatt DA, Edmunds MC, Rubio R, Berne RM, 
Lasley RD, Mentzer RM Jr. Adenosine stimulates 
glycolytic flux in isolated perfused rat hearts by A1- 
adenosine receptors. Am J Physiol 1989;257:H1952-7. 
26. Fredholm BB. Methods used to study the involvement 
of adenosine in the regulation of lipolysis. In: Paton 
DM, ed. Methods in pharmacology. New York: Ple- 
num, 1985:337-57. 
27. Fredholm BB, Dunwiddie TW. How does adenosine 
inhibit transmitter release? Trends Pharmacol Sci 
1988;9:130-4. 
28. Galifianes M, Hearse DJ. Exogenous adenosine ac- 
celerates recovery of cardiac function and improves 
coronary flow after long-term hypothermic storage 
and transplantation. J THORAC CARD[OVASC SUR6 
1992;104:151-8. 
29. Menasché P. Multinational study of the effect of 
acadesine on myocardial infarction and adverse car- 
diovascular outcomes associated with CABG surgery. 
Eur Heart J 1993;14:425. 
30. Mangano DT. Multicenter study of acadesine for 
the prevention of myocardial infarction and other 
adverse cardiovascular outcomes associated with 
coronary artery bypass graft surgery. Eur Heart J 
1994;15:66. 
31. Mullane K, Bullough D, Shapiro D. From academic 
vision to clinical reality: a case study of acadesine. 
Trends Cardiovasc Med 1993;3:227-34. 
